厄贝沙坦与福辛普利联合用药对慢性心力衰竭患者心功能的影响

目的观察厄贝沙坦与福辛普利对慢性心力衰竭(CHF)患者心功能的影响。方法选取90例CHF患者采用信封法随机分为2组各45例,对照组患者采用CHF常规治疗基础上加厄贝沙坦治疗,观察组患者在对照组基础上加福辛普利治疗,两组患者均治疗半年,治疗前后采用PHILIPS多功能彩色多普勒超声仪分别检测两组患者左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)、左室射血分数(LVEF),同时对两组患者治疗前后NYHA分级进行比较,并根据治疗前后NYHA分级改善情况进行疗效评定。结果两组患者治疗前LVEDD、LVESD、LVEF比较差异均无统计学意义,治疗后,观察组LVEDD、LVESDE及LVEF分别为(45.2±3.2)mm、(34.4±2.1)mm、(49.9±5.1)%,对照组分别为(50.3±6.2)mm、(37.8±3.2)mm、(40.5±6.7)%,观察组治疗后LVEDD、LVESD明显低于对照组,LVEF明显高于对照组,两组比较差异有统计学意义(P<0.05)。观察组治疗总有效率为88.89%,对照组为71.11%,观察组疗效明显优于对照组(P<0.05)。结论厄贝沙坦与福辛普利联合用药治疗CHF可逆转患者左心室肥厚,明显提高心脏射血分数及改善患者的心功能,值得临床推广应用。

Effect of irbesartan combined with fosinopril on cardiac function in patients withchronic heart failure

Objective To observe the effect of irbesartan combined with fosinopril on cardiac function in pa- tients with chronic heart failure （CHF）. Methods 90 cases of patients with CHF were randomly divided into two groups ,45 patients in control group were given irbesartan based on CHF conventional treatment,patients in observation group were given fosinopril on the basis of control group, two groups were all treated for six months. Left ventricular end-diastolic diameter （ LVEDD ）, left ventricular systolic diameter （ LVESD ）, left ventricular ejection fraction （LVEF） of both groups before and after treatment were detected using the PHILIPS multifunction color Doppler. NY- HA class of the two groups was also compared before and after treatment, and the efficacy was evaluated according to NYHA class improvement before and after treatment. Results There was no significant difference of LVEDD, LVESD, LVEF of the two groups before treatment, while those were （ 45.2 ± 3.2 ） mm, （ 34.4 ± 2. 1 ） mm, （ 49.9 ±5. 1 ） % in observation group and （ 50. 3±6. 2） mm, （ 37.8 ± 3.2 ） ram, （ 40. 5 ± 6. 7 ） % in control group after treat- ment, LVEDD, LVESD in observation group were significantly lower than those of control group, LVEF was signifi-cantly higher than that of control group, there was significant difference between the two groups （ P 〈 0. 05 ）. The total effective rate of observation group and control group were 88.89% and 71. 11% ,which was significantly better in ob- servation group than that in control group （ P 〈 0. 05 ）. Conclusion Irbesartan combined with fosinopril can reverse left ventricular hypertrophy in patients with CHF, significantly improved cardiac ejection fraction and cardiac function, it is worthy of clinical application.